Derek J. Maetzold, serving as both President and Chief Executive Officer of Castle Biosciences Inc. (NASDAQ:CSTL), disclosed a complex series of equity transactions on July 1, 2026, per a recent Securities and Exchange Commission filing. The activity unfolded as the company's equity traded near $24.26, a level that reflects a 38% year-to-date decline, even as the stock has recovered 18.77% over the trailing twelve months. Market analysis suggests the equity may be trading at a discount relative to fundamental metrics, particularly given the company's net cash position on its balance sheet.
The executive liquidated a total of 9,834 shares of common stock, generating gross proceeds of approximately $238,916. The sales were executed at a weighted-average price of $24.29 per share, with individual transaction prices ranging between $23.68 and $24.57. The composition of the sold shares reveals a diversified holding structure: 6,214 shares were sold from direct ownership, while the remainder were offloaded through established family trusts. Specifically, 1,357 shares were sold via The Maetzold Descendants 2020 Trust, 1,153 shares through the Derek Maetzold 2020 Irrevocable Trust, and 278 shares each from four separate Maetzold 2018 Remainder Trusts.
In a concurrent transaction, Maetzold acquired 6,214 shares by exercising fully vested stock options at a strike price of $2.39 per share, totaling approximately $14,851 in cost. Both the option exercise and the subsequent sales were governed by a Rule 10b5-1 trading plan, which the executive adopted on December 3, 2025. This pre-arranged framework is typically utilized to facilitate trades in compliance with insider trading regulations.
Following the liquidation, Maetzold's direct holding stands at 21,479 shares. His indirect exposure remains substantial, managed through multiple trust vehicles. These include DJM Grantor Retained Annuity Trust No. 6, holding 18,718 shares; DJM Grantor Retained Annuity Trust No. 7 with 44,323 shares; and DJM Grantor Retained Annuity Trust No. 8 containing 40,935 shares. Additionally, the executive retains 85,667 derivative securities in the form of outstanding stock options.
Corporate fundamentals have shown recent momentum. Castle Biosciences reported first-quarter 2026 revenue of $83.7 million, exceeding the consensus forecast of $77.46 million. However, the company posted a loss per share of $0.49, which aligned with market expectations. Product traction remains strong, with the TissueCypher Barrett’s Esophagus Test surpassing 100,000 clinical orders. Furthermore, data from Dermatology and Therapy indicates that the DecisionDx-Melanoma i31-SLNB test demonstrated superior performance compared to the Melanoma Institute Australia nomogram in assessing sentinel lymph node positivity risk.
Operational and financial developments continue to shape the investment thesis. Chief Financial Officer Frank Stokes was named a 2026 CFO Awards honoree by the Houston Business Journal. Analyst sentiment from BTIG adjusted the price target for CSTL to $40, down from $50, yet maintained a Buy rating. The adjustment reflects increased operating expense estimates associated with the company's expansion of investments. The stock closed at $24.26, up $0.15 or 0.62%, with after-hours trading showing minimal movement.